Glaxosmithkline | GSK - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.58B 316M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Aurora Cannabis CAD 40.62M 1.17M 2025-12
Bausch Health Companies USD 813M 12M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Canopy Growth CAD 28.9M 636K 2025-12
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Drreddys Laboratories INR 26.92B 3.74B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
J&J USD 6.03B 719M 2026-03
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 30.28M 606K 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Supernus Pharmaceuticals USD 118.23M 4.16M 2026-03
Takeda JPY 292B 9.21B 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Zoetis USD 588M 31M 2026-03